WO2001074327A1 - Composition for improving skin lipid barrier function - Google Patents

Composition for improving skin lipid barrier function Download PDF

Info

Publication number
WO2001074327A1
WO2001074327A1 PCT/US2000/008871 US0008871W WO0174327A1 WO 2001074327 A1 WO2001074327 A1 WO 2001074327A1 US 0008871 W US0008871 W US 0008871W WO 0174327 A1 WO0174327 A1 WO 0174327A1
Authority
WO
WIPO (PCT)
Prior art keywords
skin
composition
applying
acid
extract
Prior art date
Application number
PCT/US2000/008871
Other languages
French (fr)
Inventor
Daniel H. Maes
Jon Anderson
Kenneth D. Marenus
Thomas Mammone
Christina G. Fthenakis
Original Assignee
Color Access, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AU41931/00A priority Critical patent/AU782378B2/en
Priority to JP2001572072A priority patent/JP2003528904A/en
Priority to KR1020017015406A priority patent/KR100596595B1/en
Priority to EP00921641A priority patent/EP1272154B1/en
Application filed by Color Access, Inc. filed Critical Color Access, Inc.
Priority to PT00921641T priority patent/PT1272154E/en
Priority to ES00921641T priority patent/ES2225123T3/en
Priority to DE60014180T priority patent/DE60014180T2/en
Priority to DK00921641T priority patent/DK1272154T3/en
Priority to AT00921641T priority patent/ATE276736T1/en
Priority to PCT/US2000/008871 priority patent/WO2001074327A1/en
Priority to CA002374763A priority patent/CA2374763C/en
Publication of WO2001074327A1 publication Critical patent/WO2001074327A1/en
Priority to HK03104484.2A priority patent/HK1056821B/en
Priority to US12/103,806 priority patent/US20080213202A1/en
Priority to US13/441,164 priority patent/US8710034B2/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/32Burseraceae (Frankincense family)
    • A61K36/324Boswellia, e.g. frankincense
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36Carboxylic acids; Salts or anhydrides thereof
    • A61K8/361Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63Steroids; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/68Sphingolipids, e.g. ceramides, cerebrosides, gangliosides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783Angiosperms [Magnoliophyta]
    • A61K8/9789Magnoliopsida [dicotyledons]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/16Emollients or protectives, e.g. against radiation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/007Preparations for dry skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/08Anti-ageing preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74Biological properties of particular ingredients
    • A61K2800/75Anti-irritant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74Biological properties of particular ingredients
    • A61K2800/78Enzyme modulators, e.g. Enzyme agonists
    • A61K2800/782Enzyme inhibitors; Enzyme antagonists

Definitions

  • the invention relates to cosmetic and pharmaceutical compositions. More specifically, the invention relates to topical compositions that are useful in enhancing the function of the skin's natural lipid barrier.
  • Skin is typically characterized as consisting of three distinct layers, namely the stratum corneum, the epidermis and the dermis.
  • the stratum corneum the outermost layer, is made up of keratinized cells, surrounded by intercellular space filled with lipids.
  • the stratum corneum provides a substantial physical barrier to penetration of most substances to the lower layers of the skin. In addition to preventing transport of substances to the other skin layers, however, this barrier also aids in prevention of water loss from the skin. Both functions are primarily attributable to the presence of the lipids in the stratum corneum.
  • the skin surface lipids are a diverse group of compounds, comprising triglycerides, diglycerides, ceramides, free fatty acids, wax esters, cholesterol and cholesterol esters, and squalene.
  • the quantity and composition of the skin surface lipids differ from place to place on the body, and may to some extent be related to the number of sebaceous glands in a given area of the skin.
  • the condition of the skin surface lipids may also be affected by an essential fatty acid deficiency. Additionally, the lipid barrier is easily diminished by exposure to harsh detergents or soaps.
  • the quality of the skin lipid barrier can vary widely, depending on a number of different factors, and therefore, may not always be adequate to perform its protective function optimally.
  • cosmetic compositions frequently incorporate components which compensate for water loss. Examples of such materials are hygroscopic humectants, e.g., urea or propylene glycol, which hold water on the skin; or emollients, e.g., oleyl alcohol or caprylic/capric triglycerides .
  • Certain cosmetic components may be occlusive skin conditioners, which are used to provide an "artificial" barrier; such compounds are frequently lipids which remain on the skin surface, and include various hydrogenated oils, waxes and butters. Although many of these products provide an effective means of stemming water loss from the skin, they do have to be reapplied frequently to maintain the effect, and do not generally constitute a natural-occurring component of the stratum corneum, potentially giving rise to an unnatural, greasy feel to the skin.
  • various pharmaceutical or cosmetic active agents are also frequently used to treat the symptoms of dry skin-associated conditions; however, in many cases, particularly with pharmaceutical agents, the treatments themselves may cause undesirable side effects in the individual being treated, while ultimately resulting in no actual repair of the lipid barrier.
  • the invention relates to cosmetic and pharmaceutical compositions comprising lipid barrier-enhancing effective amounts of at least one protease inhibitor and at least one cellular differentiation enhancer.
  • the composition can also comprise, in a preferred embodiment, effective amounts of a sterol sulfate, an at least one naturally occurring skin lipid component.
  • the composition of the invention can be used in a method for strengthening the natural lipid barrier of the skin, as well as other methods of skin treatment that are made possible by the strengthening of the barrier.
  • compositions of the invention can strengthen the lipid barrier at least about 40%, relative to a placebo control, as measured by a reduction of transepidermal water loss (TEWL) after a barrier challenge, a standard measurement of barrier function.
  • TEWL transepidermal water loss
  • the compositions are capable of reducing TEWL at least about 50%, more preferably at least about 60%, and most preferably at least about 70%.
  • the invention incorporates as essential elements a protease inhibitor and a cellular differentiation enhancer.
  • protease inhibitors are compounds, usually naturally occurring, which inhibit the action of proteases in the skin. Skin proteases also occur naturally, and, among other effects, are involved in the breaking down of the collagen and elastin that is required to maintain the healthy appearance of skin.
  • the protease inhibitors used in the invention are thought to act by preventing the breakage of the desmosome bond between corneocytes at the skin surface, thereby keeping the outer layer of skin cells intact, in essence delaying desquamation. This skin layer provides a barrier to water loss, and the enhanced retention of the barrier by the delay of desquamation provides reinforces this barrier to the loss of water further.
  • a variety of protease inhibitors are known.
  • protease inhibitors include, but are not limited to, triterpenoid- containing extracts and refined compounds, for example, white birch bark extract, silver birch bark extract, Boswellia extract, bearberry extract, Centella asiatica extract, or Pygeum (Prunus) africanum extract and individual protease inhibitor compounds that may be present in these extracts, including betulinol (betulin) , betulinic acid, boswellic acid, ursolic acid, oleanolic acid, oleanol, asiaticoside, asiatic acid, and madagassic acid; phenolic-containing extracts, such as green tea extracts and apple extracts, and compounds contained therein, such as EGCG, ECG, catechins, phenylpropanoids, and phloretin; protein-based extracts, such as soy protein, or egg protease inhibitors, or cholesterol sulfate and phytosterol sulfates.
  • the amount of active material used will vary depending upon the whether an extract or isolated compound is used, the concentration of active material in a given extract, and the known potency of the active material. However, the concentration of active protease inhibitor in the final product should generally be between about 0.001 to about 10%, preferably about 0.05 to about 5%, more preferably about 0.1 to about 1%, by weight of the total composition.
  • the second component is a cellular differentiation enhancer.
  • Such compounds act in the present invention to increase the ability of the relevant epidermal cells to synthesize the lipids that constitute the primary component of the barrier.
  • the epidermal cells that produce lipids do not do so during their entire life cycle, however, but do so only at the point of differentiation. If this differentiation is delayed to the point at which the epidermal cells reach their terminal point in migration to the skin surface, the production of lipids is concurrently delayed, and therefore, their effect, if any, is diminished.
  • the differentiation enhancers used in the invention stimulate the earlier production of lipids from epidermal cells, thereby increasing the length of time over which the lipids are being produced, and presumably concurrently increasing the lipid content of the barrier.
  • differentiation inhibitors include, but are not limited to sclareolide, forskolin, 7-dehydrocholesterol , and Vitamin D3 analogs.
  • the differentiation enhancer also will be used in amount consistent with its known activity, 0.001 to 10%, preferably about .0025 to about 5%, more preferably about 0.05 to about 1%, by weight of the total composition.
  • the combination of the protease inhibitor and the differentiation enhancer is shown to have a strong effect on barrier repair when compared with control vehicles and with other compounds commonly used in skin enhancement. Specifically, on skin that had been challenged with tape stripping, it was found that combination of these two components exhibits about a 50% increase in barrier repair, as measurable by transepidermal water loss, in comparison with the placebo, after a period of three days. Thus, this combination on its own is shown to be able to increase barrier function substantially.
  • the noted combination is highly effective on its own, it has been further shown that the combination achieves even further enhancement of barrier function by its combination with certain other skin enhancement compounds. More specifically, the combination with one or more of certain specific skin enhancers.
  • the barrier repair combination is further combined with cholesterol sulfate, which in the present specification and claims is intended to refer to the corresponding plant-derived material, phytosterol sulfate.
  • Cholesterol sulfate as described in Applicants' copending application serial no. 09/246,607, incorporated herein by reference, also has an effect on the skin, by increasing the cohesion of the stratum corneum.
  • the amount of cholesterol sulfate employed is preferably about 0.05 to about 10%, preferably from about 0.5 to about 5%, most preferably about 1 to about 3%, by weight of the total composition.
  • the composition also contain other components of the naturally occurring lipid barrier.
  • the cholesterol sulfate is combined with at least one of each of fatty acids, ceramides, and a sterol, preferably cholesterol or phytosterol.
  • Fatty acids may be up to 24 carbon atoms in length. Examples of preferred fatty acids include butyric acid, caproic acid, octanoic acid, decanoic acid, dodecanoic acid, tetradecanoic acid, palmitic acid, stearic acid, linoleic acid and oleic acid. Particularly preferred are fatty acids with a C 12 to C 20 chain length.
  • the ceramides to be employed in the compositions of the invention are sphingolipids, having a sphingosine or related molecule backbone with fatty acids or ⁇ -esterified fatty acids linked to an amino group on the sphingosine, and in some cases, with saccharide moieties linked to the terminal hydroxyl of the sphingosine.
  • the compositions may contain ⁇ - esterified ceramides or acylceramides, cerebrosides, ⁇ -esterified cerebrosides, or acylglycosyl sphingolipids.
  • Particularly preferred types of ceramides for the present compositions are ceramide III and cerebrosides.
  • the lipid components each can be used in an amount of from about 0.05 to 10%, preferably 0.5 to about 5%, most preferably about 1 to about 3%, all by weight of the total composition.
  • the cholesterol sulfate and the lipid components are present in substantially equal amounts in the composition. It will be understood from the foregoing that the lipid component need not be pure lipid, but rather may be natural extracts containing one or more desirable lipids, and used in amounts consistent with attaining the concentrations recommended above.
  • compositions in effecting barrier repair or maintaining the integrity of the skin's outer layer can be applied to a number of different uses.
  • the compositions can be used to treat any condition in which a deficient or faulty barrier is a factor.
  • the compositions can be used to improve the long term moisture retention of the skin, or in prevention or treatment of dry skin conditions generally, or specific dry skin conditions, such as result from regular exposure to detergents, soaps and hot water; seasonal exposure to harsh weather conditions, e.g., cold, wind and/or sun; occupational exposure to harsh chemicals or other drying or damaging agents; or pathological conditions such as eczematous dermatides, psoriasis, ichthyoses, xerosis and the like.
  • compositions can be used in prevention of further damage to aging skin, or treatment and/or reversal of already present damage, including the appearance of fine lines and wrinkles, which are frequently associated with dry skin and the thinning of the stratum corneum that occurs with age.
  • the compositions can also be used in the treatment of a defective skin barrier, such as occurs on the soles of the feet, and palms of the hands, where the stratum corneum is very thick, but the lipid barrier is poor.
  • defective skin barriers frequently occur in association with burns, wounds, blisters, stasis ulcers and bedsores; such injuries can be expected to benefit from application of the compositions.
  • compositions of the invention are in reduction of the skin's response to irritants and sensitizers.
  • a significant percentage of the population considers itself to have sensitive skin, in that they perceive a frequent, stinging or painful response to various elements to which the skin may be exposed, be it through makeup or skin care products, environmental stimuli such as smoke or pollution, or occupational exposure to chemicals.
  • environmental stimuli such as smoke or pollution
  • occupational exposure to chemicals even normal skin can have a reaction to exposure to known irritants, such as acids.
  • the application of the compositions of the invention by increasing the integrity of the barrier, can reduce the reactivity of the skin of both normal and sensitive individuals to irritants and sensitizers.
  • the compositions can be used to reduce the reaction of the skin to the irritation caused by therapeutic acids such as alpha and beta hydroxy acids, retinoic acid, and the like, or to reduce the irritation caused by insect bites or stings, or alleviate the irritation experienced with contact dermatitis.
  • the increased cohesion of the stratum corneum brought about by the compositions of the invention also provides other benefits.
  • the stratum corneum represents an important physical barrier between the environment and the deeper skin layers as well as the internal organs. The presence of this thicker layer thus will provide a greater level of protection than is possible with weaker barrier. Perhaps the most important aspect of this effect is the enhanced self-protection from UV rays.
  • the thicker stratum corneum means an increase in the Minimal Erythemal Dose of UV which will result in sunburn or more serious skin damage.
  • the components of the invention may be beneficially combined with one or more sunscreens for an enhanced UV protective composition which provides both short- and long-term protection.
  • the invention provides sunscreen compositions comprising effective amounts of the components of the composition of the invention, and one or more sunscreens.
  • sunscreens examples include, but are not limited to, inorganic sunscreens such as titanium dioxide, zinc oxide, and iron oxide; and organic sunscreens, such as camphor derivatives, cinnamates, salicylates, benzophenones , triazines, PABA derivatives, diphenylacrylate derivatives, and dibenzoylmethane derivatives.
  • inorganic sunscreens such as titanium dioxide, zinc oxide, and iron oxide
  • organic sunscreens such as camphor derivatives, cinnamates, salicylates, benzophenones , triazines, PABA derivatives, diphenylacrylate derivatives, and dibenzoylmethane derivatives.
  • compositions of the invention are in the enhancement and prolongation of self-tanning products.
  • DHA dihydroxyacetone
  • DHA dihydroxyacetone
  • the invention provides a self-tanning composition comprising a protease inhibitor, a cell-differentiation enhancer, and an effective amount of a self-tanning agent, optionally containing cholesterol sulfate and the lipid component.
  • the self-tanner is DHA, which is usually applied in an amount of from about 2.5 to about 10% by weight of the formulation.
  • the self- tanner may also be imidazole, preferably in combination with DHA, in an amount of about 1-10%, preferably about 1.5-7.5%.
  • the compositions of the invention are employed in a manner appropriate to the intended final use of the product. For example, in the treatment of occasional dry skin due to exposure to weather or other temporary conditions, or in the treatment of occasional skin irritation, the compositions can be used on an as-needed basis until the condition is relieved.
  • the composition When being used to treat a more permanent condition, for example, a condition associated with a defective or deficient lipid barrier, particularly sensitive skin, dry skin associated with any type of aging, or the wrinkling or fine lines associated with a thinning of the stratum corneum with aging, the composition is preferably applied chronically, to prevent recurrence of the condition.
  • topical application of the composition in an amount of from about 0.1 mg/cm 2 to 2 mg/cm 2 of skin, be performed from about once per week to about 4 or 5 times daily, preferably from about 3 times a week to about 3 times daily, most preferably about once or twice per day.
  • the period of topical application may be over the lifetime of the user, preferably for a period of at least about one month, more preferably from about three months to about twenty years, more preferably from about six months to about ten years, more preferably still from about one year to about five years, thereby resulting in the treatment or prevention of the condition in question.
  • a sunscreen it is applied in the same amounts as specified above, on an as-needed basis, to mitigate the effects of exposure to the sun.
  • the composition is also applied in similar amounts, on the portion of the skin to be tanned, with repetition, again, on an as-needed basis.
  • the subjects are acclimated in an environmental room at 40% relative humidity and 70°C for 15-20 minutes .
  • a 5 cm by 1cm area is marked on the lower right cheek near the jaw line and initial water evaporation measurements are taken in three separate spots approximately 1 cm apart in a row.
  • Five cm of cello-tape is placed on the skin in the outlined area, starting from the top of the cheek and after one firm stroke in each direction it is removed by gently pulling in a downward direction parallel to the skin.
  • the procedure is repeated and water evaporation is measured after every five strips until the barrier is disrupted as indicated by a minimum of 18g/sq.m hr on one of the three spots. Both sides of the face are stripped in the same way.
  • the subjects returned for TEWL evaluation 1,2 and 3 days after tape stripping of the skin to monitor the repair.
  • Barrier repair is evaluated by first challenging the skin as described above. One side is product-treated 2 times a day, and the other is the untreated control. Repair is measured in the increase in the recovery of the skin on the stripped and treated site compared to the stripped untreated site. From this, total repair is calculated over three days by calculating the change in the area parameter. The smaller the area, the faster the repair.
  • Treatment products are (1) a composition containing 0.1% sclareolide and 0.2% white birch extract; (2) a composition containing 0.1% sclareolide and 0.2% boswellic acid; (3) a composition containing .2% each of phytocohesine (phytosterol sulfate), cennamides (wheat-derived ceramides), boswellic acid, cholesterol, and linoleic acid, and .1% sclareolide.
  • the results obtained indicate for composition (1) , barrier repair is 50% over placebo; for composition (2), repair is 59% over placebo, and composition (3) is shows barrier repair at 78% over the placebo, each composition therefore showing substantial efficacy in barrier repair .

Abstract

The invention relates to a composition for topical application to the skin comprising effective amounts of a protease inhibitor and a cell differentiation enhancer. The composition is useful in promoting skin lipid barrier repair and maintaining the integrity of the lipid barrier. In this regard, the compositions can be used in the treatment and prevention of dry skin, and associated chrono/photo-aging conditions, in the treatment and prevention of irritation on the skin, in the treatment and prevention of UV-related damage to the skin, and in the enhancement of the retention of self-tanning.

Description

COMPOSITION FOR IMPROVING SKIN LIPID BARRIER FUNCTION
Field of the Invention
The invention relates to cosmetic and pharmaceutical compositions. More specifically, the invention relates to topical compositions that are useful in enhancing the function of the skin's natural lipid barrier. Background of the Invention
Skin is typically characterized as consisting of three distinct layers, namely the stratum corneum, the epidermis and the dermis. The stratum corneum, the outermost layer, is made up of keratinized cells, surrounded by intercellular space filled with lipids. The stratum corneum provides a substantial physical barrier to penetration of most substances to the lower layers of the skin. In addition to preventing transport of substances to the other skin layers, however, this barrier also aids in prevention of water loss from the skin. Both functions are primarily attributable to the presence of the lipids in the stratum corneum.
There are two sources of the skin surface lipids making up this important barrier: sebaceous glands and the epidermis. The lipids are a diverse group of compounds, comprising triglycerides, diglycerides, ceramides, free fatty acids, wax esters, cholesterol and cholesterol esters, and squalene. The quantity and composition of the skin surface lipids differ from place to place on the body, and may to some extent be related to the number of sebaceous glands in a given area of the skin. The condition of the skin surface lipids may also be affected by an essential fatty acid deficiency. Additionally, the lipid barrier is easily diminished by exposure to harsh detergents or soaps. It is apparent, then, that the quality of the skin lipid barrier can vary widely, depending on a number of different factors, and therefore, may not always be adequate to perform its protective function optimally. As an attempt to compensate for what may be a less than adequate lipid barrier, cosmetic compositions frequently incorporate components which compensate for water loss. Examples of such materials are hygroscopic humectants, e.g., urea or propylene glycol, which hold water on the skin; or emollients, e.g., oleyl alcohol or caprylic/capric triglycerides . Certain cosmetic components may be occlusive skin conditioners, which are used to provide an "artificial" barrier; such compounds are frequently lipids which remain on the skin surface, and include various hydrogenated oils, waxes and butters. Although many of these products provide an effective means of stemming water loss from the skin, they do have to be reapplied frequently to maintain the effect, and do not generally constitute a natural-occurring component of the stratum corneum, potentially giving rise to an unnatural, greasy feel to the skin. In addition, various pharmaceutical or cosmetic active agents are also frequently used to treat the symptoms of dry skin-associated conditions; however, in many cases, particularly with pharmaceutical agents, the treatments themselves may cause undesirable side effects in the individual being treated, while ultimately resulting in no actual repair of the lipid barrier.
The most desirable situation, from a functional point of view, is to find a way to enhance the skin's own ability to maintain and/or repair the strength of its barrier, so that the protective barrier formed is completely natural. It has now been discovered that a combination of specific skin active agents results in an unexpected increase in the strength of the natural barrier, by stimulating the production and maintenance of the barrier's naturally occurring components. There is thus provided a new type of cosmetic or pharmaceutical composition which functions by enhancing the skin's own functions, resulting in a more natural means of preventing dry skin and other undesirable results of a deficient lipid barrier. Summary of the Invention
The invention relates to cosmetic and pharmaceutical compositions comprising lipid barrier-enhancing effective amounts of at least one protease inhibitor and at least one cellular differentiation enhancer. The composition can also comprise, in a preferred embodiment, effective amounts of a sterol sulfate, an at least one naturally occurring skin lipid component. The composition of the invention can be used in a method for strengthening the natural lipid barrier of the skin, as well as other methods of skin treatment that are made possible by the strengthening of the barrier.
Detailed Description of the Invention
The combined actives of the composition of the invention have been found to be highly effective in stimulating the repair of a damaged lipid barrier, and therefore, are shown to be useful as well in maintenance of a normal and healthy lipid barrier. For the purposes of the present invention and claims, these abilities will be referred to as strengthening the lipid barrier. The compositions of the invention can strengthen the lipid barrier at least about 40%, relative to a placebo control, as measured by a reduction of transepidermal water loss (TEWL) after a barrier challenge, a standard measurement of barrier function. Preferably, the compositions are capable of reducing TEWL at least about 50%, more preferably at least about 60%, and most preferably at least about 70%. The invention incorporates as essential elements a protease inhibitor and a cellular differentiation enhancer. Protease inhibitors are compounds, usually naturally occurring, which inhibit the action of proteases in the skin. Skin proteases also occur naturally, and, among other effects, are involved in the breaking down of the collagen and elastin that is required to maintain the healthy appearance of skin. In the present case, the protease inhibitors used in the invention are thought to act by preventing the breakage of the desmosome bond between corneocytes at the skin surface, thereby keeping the outer layer of skin cells intact, in essence delaying desquamation. This skin layer provides a barrier to water loss, and the enhanced retention of the barrier by the delay of desquamation provides reinforces this barrier to the loss of water further. A variety of protease inhibitors are known. Examples of useful protease inhibitors include, but are not limited to, triterpenoid- containing extracts and refined compounds, for example, white birch bark extract, silver birch bark extract, Boswellia extract, bearberry extract, Centella asiatica extract, or Pygeum (Prunus) africanum extract and individual protease inhibitor compounds that may be present in these extracts, including betulinol (betulin) , betulinic acid, boswellic acid, ursolic acid, oleanolic acid, oleanol, asiaticoside, asiatic acid, and madagassic acid; phenolic-containing extracts, such as green tea extracts and apple extracts, and compounds contained therein, such as EGCG, ECG, catechins, phenylpropanoids, and phloretin; protein-based extracts, such as soy protein, or egg protease inhibitors, or cholesterol sulfate and phytosterol sulfates. Preferred protease inhibitors are triterpenoids, particularly boswellic acid, betulinol, and betulinic acid, or extracts containing same in substantial quantities.
It will be recognized from the foregoing that either an extract or the individual protease inhibitor can be used, and that the individual protease inhibitors can also be found in other types of extracts. The amount of active material used will vary depending upon the whether an extract or isolated compound is used, the concentration of active material in a given extract, and the known potency of the active material. However, the concentration of active protease inhibitor in the final product should generally be between about 0.001 to about 10%, preferably about 0.05 to about 5%, more preferably about 0.1 to about 1%, by weight of the total composition.
The second component is a cellular differentiation enhancer. Such compounds act in the present invention to increase the ability of the relevant epidermal cells to synthesize the lipids that constitute the primary component of the barrier. The epidermal cells that produce lipids do not do so during their entire life cycle, however, but do so only at the point of differentiation. If this differentiation is delayed to the point at which the epidermal cells reach their terminal point in migration to the skin surface, the production of lipids is concurrently delayed, and therefore, their effect, if any, is diminished. The differentiation enhancers used in the invention stimulate the earlier production of lipids from epidermal cells, thereby increasing the length of time over which the lipids are being produced, and presumably concurrently increasing the lipid content of the barrier. Several types of cellular differentiation inhibitors are known, and these include, but are not limited to sclareolide, forskolin, 7-dehydrocholesterol , and Vitamin D3 analogs. The differentiation enhancer also will be used in amount consistent with its known activity, 0.001 to 10%, preferably about .0025 to about 5%, more preferably about 0.05 to about 1%, by weight of the total composition.
The combination of the protease inhibitor and the differentiation enhancer is shown to have a strong effect on barrier repair when compared with control vehicles and with other compounds commonly used in skin enhancement. Specifically, on skin that had been challenged with tape stripping, it was found that combination of these two components exhibits about a 50% increase in barrier repair, as measurable by transepidermal water loss, in comparison with the placebo, after a period of three days. Thus, this combination on its own is shown to be able to increase barrier function substantially.
Although the noted combination is highly effective on its own, it has been further shown that the combination achieves even further enhancement of barrier function by its combination with certain other skin enhancement compounds. More specifically, the combination with one or more of certain specific skin enhancers. In a preferred embodiment, the barrier repair combination is further combined with cholesterol sulfate, which in the present specification and claims is intended to refer to the corresponding plant-derived material, phytosterol sulfate. Cholesterol sulfate, as described in Applicants' copending application serial no. 09/246,607, incorporated herein by reference, also has an effect on the skin, by increasing the cohesion of the stratum corneum.
Thus, its combination with the protease inhibitor/differentiation enhancer even further strengthens the ability of the composition maintain the integrity of the stratum corneum. The amount of cholesterol sulfate employed is preferably about 0.05 to about 10%, preferably from about 0.5 to about 5%, most preferably about 1 to about 3%, by weight of the total composition.
In all formulations in which cholesterol sulfate is employed, and in a particularly preferred embodiment, it is preferred that the composition also contain other components of the naturally occurring lipid barrier. In a particularly preferred embodiment, the cholesterol sulfate is combined with at least one of each of fatty acids, ceramides, and a sterol, preferably cholesterol or phytosterol. Fatty acids may be up to 24 carbon atoms in length. Examples of preferred fatty acids include butyric acid, caproic acid, octanoic acid, decanoic acid, dodecanoic acid, tetradecanoic acid, palmitic acid, stearic acid, linoleic acid and oleic acid. Particularly preferred are fatty acids with a C12 to C20 chain length.
The ceramides to be employed in the compositions of the invention are sphingolipids, having a sphingosine or related molecule backbone with fatty acids or ω-esterified fatty acids linked to an amino group on the sphingosine, and in some cases, with saccharide moieties linked to the terminal hydroxyl of the sphingosine. In particular, the compositions may contain ω- esterified ceramides or acylceramides, cerebrosides, ω-esterified cerebrosides, or acylglycosyl sphingolipids. Particularly preferred types of ceramides for the present compositions are ceramide III and cerebrosides.
In those compositions in which cholesterol sulfate is combined with these lipids, the lipid components each can be used in an amount of from about 0.05 to 10%, preferably 0.5 to about 5%, most preferably about 1 to about 3%, all by weight of the total composition. In a particularly preferred embodiment, the cholesterol sulfate and the lipid components are present in substantially equal amounts in the composition. It will be understood from the foregoing that the lipid component need not be pure lipid, but rather may be natural extracts containing one or more desirable lipids, and used in amounts consistent with attaining the concentrations recommended above.
The effect of the present compositions in effecting barrier repair or maintaining the integrity of the skin's outer layer can be applied to a number of different uses. For example, the compositions can be used to treat any condition in which a deficient or faulty barrier is a factor. In this regard, the compositions can be used to improve the long term moisture retention of the skin, or in prevention or treatment of dry skin conditions generally, or specific dry skin conditions, such as result from regular exposure to detergents, soaps and hot water; seasonal exposure to harsh weather conditions, e.g., cold, wind and/or sun; occupational exposure to harsh chemicals or other drying or damaging agents; or pathological conditions such as eczematous dermatides, psoriasis, ichthyoses, xerosis and the like. It is also well-known that dry skin is commonly associated with aging (both intrinsic and photoaging) , and the compositions can be used in prevention of further damage to aging skin, or treatment and/or reversal of already present damage, including the appearance of fine lines and wrinkles, which are frequently associated with dry skin and the thinning of the stratum corneum that occurs with age. The compositions can also be used in the treatment of a defective skin barrier, such as occurs on the soles of the feet, and palms of the hands, where the stratum corneum is very thick, but the lipid barrier is poor. In addition, defective skin barriers frequently occur in association with burns, wounds, blisters, stasis ulcers and bedsores; such injuries can be expected to benefit from application of the compositions.
A further use of the compositions of the invention is in reduction of the skin's response to irritants and sensitizers. A significant percentage of the population considers itself to have sensitive skin, in that they perceive a frequent, stinging or painful response to various elements to which the skin may be exposed, be it through makeup or skin care products, environmental stimuli such as smoke or pollution, or occupational exposure to chemicals. In addition, even normal skin can have a reaction to exposure to known irritants, such as acids. As it is well known that the stratum corneum and lipids constitute the first line of defense against irritants, by providing a physical barrier to permeability of such materials to the lower skin layers, the application of the compositions of the invention, by increasing the integrity of the barrier, can reduce the reactivity of the skin of both normal and sensitive individuals to irritants and sensitizers. In one embodiment, for example, the compositions can be used to reduce the reaction of the skin to the irritation caused by therapeutic acids such as alpha and beta hydroxy acids, retinoic acid, and the like, or to reduce the irritation caused by insect bites or stings, or alleviate the irritation experienced with contact dermatitis. The increased cohesion of the stratum corneum brought about by the compositions of the invention also provides other benefits. The stratum corneum represents an important physical barrier between the environment and the deeper skin layers as well as the internal organs. The presence of this thicker layer thus will provide a greater level of protection than is possible with weaker barrier. Perhaps the most important aspect of this effect is the enhanced self-protection from UV rays. The thicker stratum corneum means an increase in the Minimal Erythemal Dose of UV which will result in sunburn or more serious skin damage. In connection with this aspect of the invention, the components of the invention may be beneficially combined with one or more sunscreens for an enhanced UV protective composition which provides both short- and long-term protection. Thus, the invention provides sunscreen compositions comprising effective amounts of the components of the composition of the invention, and one or more sunscreens. Examples of useful sunscreens include, but are not limited to, inorganic sunscreens such as titanium dioxide, zinc oxide, and iron oxide; and organic sunscreens, such as camphor derivatives, cinnamates, salicylates, benzophenones , triazines, PABA derivatives, diphenylacrylate derivatives, and dibenzoylmethane derivatives. In such sunscreen compositions, the components of the invention are present in the amounts described above, and the respective sunscreens are present in the amounts normally used for UV protection.
An additional use of the compositions of the invention is in the enhancement and prolongation of self-tanning products. One of the recognized limitations of self-tanners, which are normally based on dihydroxyacetone (DHA) as the active component, is that the tan on the skin lasts only as long as the skin cells receiving the DHA remain in place. In the normal course of events, then, a self-applied tan usually lasts no more than 5 days, i.e., for as long as it takes for the stratum corneum layer to which the DHA was applied to fully turn over. When the compositions of the invention are combined with DHA, or any other self-tanning agent, in a typical self-tanning formulation, however, the rate of turnover of the stratum corneum to which the composition is applied is slowed down, thereby permitting a longer rate of retention of the "tanned" cells, and thus prolonging the length of time the tan remains visible on the skin. Thus, the invention provides a self-tanning composition comprising a protease inhibitor, a cell-differentiation enhancer, and an effective amount of a self-tanning agent, optionally containing cholesterol sulfate and the lipid component. In a preferred embodiment, the self-tanner is DHA, which is usually applied in an amount of from about 2.5 to about 10% by weight of the formulation. The self- tanner may also be imidazole, preferably in combination with DHA, in an amount of about 1-10%, preferably about 1.5-7.5%. The compositions of the invention are employed in a manner appropriate to the intended final use of the product. For example, in the treatment of occasional dry skin due to exposure to weather or other temporary conditions, or in the treatment of occasional skin irritation, the compositions can be used on an as-needed basis until the condition is relieved. When being used to treat a more permanent condition, for example, a condition associated with a defective or deficient lipid barrier, particularly sensitive skin, dry skin associated with any type of aging, or the wrinkling or fine lines associated with a thinning of the stratum corneum with aging, the composition is preferably applied chronically, to prevent recurrence of the condition. For this purpose, it is suggested as an example that topical application of the composition, in an amount of from about 0.1 mg/cm2 to 2 mg/cm2 of skin, be performed from about once per week to about 4 or 5 times daily, preferably from about 3 times a week to about 3 times daily, most preferably about once or twice per day. By "chronic" application, it is meant herein that the period of topical application may be over the lifetime of the user, preferably for a period of at least about one month, more preferably from about three months to about twenty years, more preferably from about six months to about ten years, more preferably still from about one year to about five years, thereby resulting in the treatment or prevention of the condition in question. When the composition is used in conjunction with a sunscreen, it is applied in the same amounts as specified above, on an as-needed basis, to mitigate the effects of exposure to the sun. When used in combination with a self-tanner, the composition is also applied in similar amounts, on the portion of the skin to be tanned, with repetition, again, on an as-needed basis.
The invention is further illustrated by the following non- limiting examples: EXAMPLES
Example 1.
A study is conducted to determine the efficacy of certain compositions in enhancing repair of the lipid barrier. Female volunteers with normal skin, who are in good general health, free of any dermatological disorders, participate in the study. Their skin barrier is challenged by tape stripping according to the procedure outlined below. After their evaluation, the subjects receive a treatment every day on the right side of their face. They are also given the product containing the actives to use once every night for three nights, on the right side of the face only, the left side being the untreated control side. A separate group is given a placebo, without actives, as treatment product.
To challenge the barrier, the subjects are acclimated in an environmental room at 40% relative humidity and 70°C for 15-20 minutes . A 5 cm by 1cm area is marked on the lower right cheek near the jaw line and initial water evaporation measurements are taken in three separate spots approximately 1 cm apart in a row. Five cm of cello-tape is placed on the skin in the outlined area, starting from the top of the cheek and after one firm stroke in each direction it is removed by gently pulling in a downward direction parallel to the skin. The procedure is repeated and water evaporation is measured after every five strips until the barrier is disrupted as indicated by a minimum of 18g/sq.m hr on one of the three spots. Both sides of the face are stripped in the same way. The subjects returned for TEWL evaluation 1,2 and 3 days after tape stripping of the skin to monitor the repair.
Barrier repair is evaluated by first challenging the skin as described above. One side is product-treated 2 times a day, and the other is the untreated control. Repair is measured in the increase in the recovery of the skin on the stripped and treated site compared to the stripped untreated site. From this, total repair is calculated over three days by calculating the change in the area parameter. The smaller the area, the faster the repair.
Treatment products are (1) a composition containing 0.1% sclareolide and 0.2% white birch extract; (2) a composition containing 0.1% sclareolide and 0.2% boswellic acid; (3) a composition containing .2% each of phytocohesine (phytosterol sulfate), cennamides (wheat-derived ceramides), boswellic acid, cholesterol, and linoleic acid, and .1% sclareolide. The results obtained indicate for composition (1) , barrier repair is 50% over placebo; for composition (2), repair is 59% over placebo, and composition (3) is shows barrier repair at 78% over the placebo, each composition therefore showing substantial efficacy in barrier repair .

Claims

What we claim is :
1. A composition for topical application to the skin comprising effective amounts of at least one protease inhibitor and at least one cell differentiation enhancer.
2. The composition of claim 1 in which the protease inhibitor is selected from the group consisting of triterpenoid-containing extracts, and active components thereof, phenolic-containing extracts and active components thereof, and protein-based extract and active components thereof.
3. The composition of claim 1 in which the protease inhibitor is selected from the group consisting of white birch extract, silver birch extract, Boswellia extract, bearberry extract, Centella asiatica extract, Pygeum (Prunus) africanum extract, betulinol, betulinic acid, boswellic acid, ursolic acid, oleanolic acid, oleanol, asiaticoside, asiatic acid, madagassic acid, green tea extract, apple extracts, EGCG, ECG, catechins, phenylpropanoids , phloretin, soy protein, egg protease inhibitors, cholesterol sulfate, phytosterol sulfate, and combinations thereof.
4. The composition of claim 3 in which the protease inhibitor is selected from the group consisting of white birch extract, betulinol, betulinic acid, Boswellia extract, boswellic acid, and combinations thereof.
5. The composition of claim 1 in which the cell differentiation enhancer is selected from the group consisting of forskolin, sclareolide, 7-dehydrocholesterol, and Vitamin D3 analogs.
6. The composition of claim 5 in which the enhancer is sclareolide .
7. The composition of claim 1 comprising about .001 to about 10% of a protease inhibitor and about 0.001-10% cell differentiation enhancer.
8. The composition of claim 1 comprising about 0.1 to about 1% of a protease inhibitor and about .05-1% cell differentiation enhancer .
9. The composition of claim 8 in which the inhibitor is white birch extract, betulinol, or boswellic acid and the enhancer is sclareolide.
10. The composition of claim 1 which also contains cholesterol sulfate .
11. The composition of claim 10 which also contains at least one fatty acid, at least one ceramide, and at least one sterol.
12. The composition of claim 11 in which the fatty acid is a C12- C20 fatty acid.
13. The composition of claim 11 containing about 0.05 to 10% of each of cholesterol sulfate or phytosterol sulfate, fatty acid, ceramide, and sterol.
14. The composition of claim 1 which further comprises an effective amount of at least one self-tanning agent.
15. The composition of claim 14 in which the self-tanning agent is DHA.
16. The composition of claim 1 which further comprises at least one sunscreen.
17. A method for treatment or prevention of dry skin which comprises applying to the skin a composition according to claim 1.
18. A method for treatment or prevention of dry skin which comprises applying to the skin a composition according to claim 9.
19. A method for treatment or prevention of dry skin which comprises applying to the skin a composition according to claim 11.
20. A method for reducing or preventing skin's response to irritants or sensitizers comprising applying to the skin a composition of claim 1.
21. A method for reducing or preventing skin's response to irritants or sensitizers comprising applying to the skin a composition of claim 9.
22. A method for reducing or preventing skin's response to irritants or sensitizers comprising applying to the skin a composition of claim 11.
23. A method for protecting skin against effects of exposure to UV radiation comprising applying to the skin a composition of claim 1.
24. A method for protecting skin against effects of exposure to UV radiation comprising applying to the skin a composition of claim 9.
25. A method for protecting skin against effects of exposure to UV radiation comprising applying to the skin a composition of claim 11.
26. A method for protecting skin against effects of exposure to UV radiation comprising applying to the skin a composition of claim 16.
27. A method for tanning the skin without exposure to the sun comprising applying to the skin a composition according to claim 14.
28. A method for tanning the skin without exposure to the sun comprising applying to the skin a composition according to claim 15.
PCT/US2000/008871 2000-04-04 2000-04-04 Composition for improving skin lipid barrier function WO2001074327A1 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
ES00921641T ES2225123T3 (en) 2000-04-04 2000-04-04 COMPOSITION TO IMPROVE THE FUNCTION OF THE SKIN LIPIDIC BARRIER.
KR1020017015406A KR100596595B1 (en) 2000-04-04 2000-04-04 Composition for Improving Skin Lipid Barrier Function
EP00921641A EP1272154B1 (en) 2000-04-04 2000-04-04 Composition for improving skin lipid barrier function
DK00921641T DK1272154T3 (en) 2000-04-04 2000-04-04 Composition for improving skin lipid barrier function
PT00921641T PT1272154E (en) 2000-04-04 2000-04-04 COMPOSITION FOR IMPROVING THE FUNCTION OF LIPIDAL SKIN BARRIER
JP2001572072A JP2003528904A (en) 2000-04-04 2000-04-04 Composition for improving skin lipid barrier function
DE60014180T DE60014180T2 (en) 2000-04-04 2000-04-04 PREPARATION FOR IMPROVING THE EPITHELIAL LIPID BARRIER FUNCTION
AU41931/00A AU782378B2 (en) 2000-04-04 2000-04-04 Composition for improving skin lipid barrier function
AT00921641T ATE276736T1 (en) 2000-04-04 2000-04-04 PREPARATION FOR IMPROVING EPITHELIAL LIPID BARRIER FUNCTION
PCT/US2000/008871 WO2001074327A1 (en) 2000-04-04 2000-04-04 Composition for improving skin lipid barrier function
CA002374763A CA2374763C (en) 2000-04-04 2000-04-04 Composition for improving skin lipid barrier function
HK03104484.2A HK1056821B (en) 2000-04-04 2003-06-23 Composition for improving skin lipid barrier function
US12/103,806 US20080213202A1 (en) 2000-04-04 2008-04-16 Composition For Improving Skin Lipid Barrier Function
US13/441,164 US8710034B2 (en) 2000-04-04 2012-04-06 Method and composition for improving skin barrier function

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2000/008871 WO2001074327A1 (en) 2000-04-04 2000-04-04 Composition for improving skin lipid barrier function

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US55498400A A-371-Of-International 2000-04-04 2000-04-04
US12/103,806 Continuation US20080213202A1 (en) 2000-04-04 2008-04-16 Composition For Improving Skin Lipid Barrier Function

Publications (1)

Publication Number Publication Date
WO2001074327A1 true WO2001074327A1 (en) 2001-10-11

Family

ID=21741232

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/008871 WO2001074327A1 (en) 2000-04-04 2000-04-04 Composition for improving skin lipid barrier function

Country Status (13)

Country Link
US (2) US20080213202A1 (en)
EP (1) EP1272154B1 (en)
JP (1) JP2003528904A (en)
KR (1) KR100596595B1 (en)
AT (1) ATE276736T1 (en)
AU (1) AU782378B2 (en)
CA (1) CA2374763C (en)
DE (1) DE60014180T2 (en)
DK (1) DK1272154T3 (en)
ES (1) ES2225123T3 (en)
HK (1) HK1056821B (en)
PT (1) PT1272154E (en)
WO (1) WO2001074327A1 (en)

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002030385A2 (en) * 2000-09-30 2002-04-18 Henkel Kommanditgesellschaft Auf Aktien Anti-inflammatory active ingredients
WO2002080880A2 (en) * 2002-05-02 2002-10-17 Priscilla S.R.L. Unipersonale Anti-stretch mark preparation and method thereof
US6576660B1 (en) 1997-10-31 2003-06-10 Arch Development Corporation Methods and compositions for regulation of 5-α-reductase activity
US6696484B2 (en) 1997-10-31 2004-02-24 University Of Chicago Office Of Technology And Intellectual Property Method and compositions for regulation of 5-alpha reductase activity
EP1442736A1 (en) * 2003-02-03 2004-08-04 L'oreal Use of 3-acetyl-11-keto-boswellic acid or of a plant extract containing the same for the reduction of wrinkles
WO2005105019A1 (en) * 2004-04-30 2005-11-10 Kao Corporation Winkle reduction agent and cosmetic skin preparation
WO2006007487A3 (en) * 2004-07-01 2006-08-17 E L Management Corp Cosmetic compositions and methods containing a tanning agent and liposome-enscapsulated ursolic acid
KR100871962B1 (en) * 2004-07-01 2008-12-08 이-엘 매니지먼트 코포레이션 Cosmetic compositions and methods containing a tanning agent and liposome-encapsulated ursolic acid
WO2008155048A1 (en) * 2007-06-20 2008-12-24 Cognis Ip Management Gmbh Cosmetic compositions comprising sclareolide and hesperidin methyl chalcone
FR2930445A1 (en) * 2008-04-29 2009-10-30 Am Phyto Conseil Sarl USE OF A COMPOSITION CONTAINING 7-DEHYDROCHOLESTEROL OR A NATURAL EXTRACT OF MICROORGANISM OR PLANT VEGETABLE OR ANIMAL
US20100040706A1 (en) * 2008-06-06 2010-02-18 Lvmh Recherche Method of anti-ageing cosmetic care by stimulation of survivin expression
FR2942962A1 (en) * 2009-03-11 2010-09-17 Oreal Cosmetic process for caring skin, which is fragile and damaged by chemical, mechanical and/or physical treatment, comprises applying a composition comprising at least one dihydrochalcone or its derivatives, in a medium, on the skin
WO2013038316A1 (en) 2011-09-12 2013-03-21 Stora Enso Oyj Method for preparation of betulinic acid
WO2013038314A1 (en) 2011-09-12 2013-03-21 Stora Enso Oyj Method for preparation of betulinic acid
EP2789369A1 (en) 2013-04-14 2014-10-15 Symrise AG A composition for lightening skin and hair
EP3097905A1 (en) 2015-05-28 2016-11-30 Symrise AG Cosmetic compositions
WO2017215729A1 (en) 2016-05-30 2017-12-21 Symrise Ag Cosmetic compositions comprising sclareolide
WO2018001485A1 (en) 2016-06-30 2018-01-04 Symrise Ag Medicament and cosmetic composition comprising resorcinol derivatives
EP3133939A4 (en) * 2014-04-23 2018-03-28 Lifeline Nutraceuticals Corporation Topical compositions and methods for reducing oxidative stress
WO2023167867A1 (en) 2022-03-01 2023-09-07 Isp Investments Llc Sclareol or sclareolide for improving scalp conditions and hair growth

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001316221A (en) * 2000-05-10 2001-11-13 Naris Cosmetics Co Ltd Antiaging agent and cosmetic
PL209905B1 (en) * 2004-01-15 2011-11-30 Bringwell Internat Ab Formulation for treating obesity and associated metabolic syndrome
GB0413954D0 (en) * 2004-06-22 2004-07-28 Altunkaya Ali Compositions for topical treatment
US20080268077A1 (en) * 2004-10-14 2008-10-30 Symrise Gmbh & Co. Kg Process for Strengthening the Barrier Function of Undamaged Skin
JP4938302B2 (en) * 2005-12-12 2012-05-23 ポーラ化成工業株式会社 Skin preparation for improving skin barrier function
FI121468B (en) * 2006-06-07 2010-11-30 Valtion Teknillinen Compounds derived from betulin as antimicrobial agents
US20100303745A1 (en) * 2009-05-29 2010-12-02 Brownberry Skin bronzer
US8435541B2 (en) * 2010-09-02 2013-05-07 Bath & Body Works Brand Management, Inc. Topical compositions for inhibiting matrix metalloproteases and providing antioxidative activities
US10137073B2 (en) 2016-01-02 2018-11-27 L'oreal Cosmetic compositions comprising ceramides and cholesterol
EP3981378A1 (en) 2020-10-09 2022-04-13 Evonik Operations GmbH Compositions comprising ceramide, polyglycerol carboxylic acid ester and cholesterol

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995025524A1 (en) * 1994-03-18 1995-09-28 Lvmh Recherche USE OF GINSENOSIDE Ro OR A PLANT EXTRACT CONTAINING SAME TO PROMOTE COLLAGEN SYNTHESIS
EP0717983A1 (en) * 1994-12-20 1996-06-26 Unilever Plc Cosmetic compositions containing betulinic acid
WO1999024009A1 (en) * 1997-11-07 1999-05-20 Lvmh Recherche Uses of d-xylose, the esters thereof and oligosaccharides containing xylose for improving the functionality of epidermal cells
WO1999062481A1 (en) * 1998-05-29 1999-12-09 Guerlain S.A. Cosmetic treatment method for fighting against skin ageing effects
WO1999063978A2 (en) * 1998-06-09 1999-12-16 R.J. Reynolds Tobacco Company Methods of treating microbial infection and therapeutic formulations therefor
EP0976396A1 (en) * 1998-07-30 2000-02-02 L'oreal Cosmetic or pharmaceutical patch and packaging

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60161911A (en) 1984-01-31 1985-08-23 Kanebo Ltd Skin cosmetic
US4760096A (en) * 1985-09-27 1988-07-26 Schering Corporation Moisturizing skin preparation
US4992477A (en) * 1988-04-04 1991-02-12 Warner-Lambert Company Skin moisturizing composition and method of preparing same
US5084270A (en) * 1988-04-22 1992-01-28 Revlon, Inc. Cosmetic compositions containing N-alkoxyalkylamides
WO1990001323A1 (en) 1988-08-12 1990-02-22 Bernstein Joel E Method and composition for treating and preventing dry skin disorders
US5508034A (en) 1988-08-12 1996-04-16 Genderm Corporation Method and composition for treating and preventing dry skin disorders
WO1990010430A1 (en) 1989-03-07 1990-09-20 Plough, Inc. Liposome compositions
JPH0551314A (en) 1991-08-20 1993-03-02 Kanebo Ltd Skin cosmetics
JP2567317B2 (en) 1991-11-14 1996-12-25 花王株式会社 Hair cosmetics
JPH05310526A (en) * 1992-05-07 1993-11-22 Eisai Co Ltd Cell differentiation promotor
KR0179393B1 (en) 1992-06-19 1999-03-20 린다 에스. 스티븐슨 Lipids for epidermal moisturization and repair of barrier function
FR2694289B1 (en) * 1992-07-29 1994-10-14 Oreal Sulfur, fluorinated and polyglycerolated amphiphilic compounds, cosmetic or pharmaceutical composition comprising them, process for preparation and vesicles formed.
US5310759A (en) * 1992-08-12 1994-05-10 Bockman Richard S Methods of protecting and preserving connective and support tissues
US5885565A (en) 1993-03-19 1999-03-23 Cellegy Pharmaceuticals Inc. Methods for inducing phase separation of epithelial lipid bilayers
CA2097997C (en) 1993-06-08 2006-01-10 Jose P. Sestelo Vitamin d compounds and method of preparing these compounds
DK72593D0 (en) * 1993-06-18 1993-06-18 Symbicom Ab RECOMBINANT PROTEIN
US5589194A (en) * 1993-09-20 1996-12-31 Minnesota Mining And Manufacturing Company Method of encapsulation and microcapsules produced thereby
FR2714829B1 (en) * 1994-01-10 1996-02-02 Oreal Cosmetic and / or dermatological composition for the treatment of aging containing ceramides, its use.
WO1995019762A1 (en) * 1994-01-19 1995-07-27 Taisho Pharmaceutical Co., Ltd. Dermatologic composition
FR2716622B1 (en) * 1994-02-28 1996-04-12 Oreal Cosmetic self-tanning compositions based on dihydroxyacetone, process for preparation and use.
IT1270602B (en) * 1994-07-12 1997-05-07 Indena Spa ESCULOSIDE BASED FORMULATIONS AND THEIR USE IN THE PHARMACEUTICAL AND COSMETIC FIELD
FR2727626B1 (en) * 1994-12-05 1997-01-17 Oreal SELF-TANNING COSMETIC COMPOSITIONS BASED ON DIHYDROXYACETONE, ALKYLPOLYOSIDES AND FATTY ALCOHOLS
GB9500024D0 (en) 1995-01-04 1995-03-01 Sod Conseils Rech Applic Treatment of excessive cell proliferation disorders
FR2752527B1 (en) 1996-08-22 1998-11-13 Lvmh Rech USE OF A BERTHOLLETIA EXTRACT IN THE COSMETIC OR PHARMACEUTICAL AREA, ESPECIALLY DERMATOLOGICAL, AND FOR THE PREPARATION OF CELL CULTURE MEDIA
US6004568A (en) 1995-02-17 1999-12-21 Lvmh Recherche Cosmetic or pharmaceutical, particularly dermatological, composition containing a Bertholletia extract
US5658947A (en) 1995-03-21 1997-08-19 Board Of Trustees Of The University Of Illinois Method and composition for selectively inhibiting melanoma using betalinic acid
FR2732680B1 (en) 1995-04-05 1997-05-09 Oreal CERAMID-LIKE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THEIR USE
US5738856A (en) * 1995-11-03 1998-04-14 Ocular Research Of Boston, Inc. Skin care preparation and method
CA2262870C (en) * 1996-04-04 2008-01-29 Cilag Ag Liposome-based topical vitamin d formulation
JP3426436B2 (en) * 1996-05-28 2003-07-14 カネボウ株式会社 Skin cosmetics
US5705145A (en) * 1996-08-21 1998-01-06 E-L Management Corp. Skin tanning compositions and method
DE19644637C1 (en) * 1996-10-17 1998-08-13 Lancaster Group Ag Cosmetic tanning and sunscreen agent
DE19642872C1 (en) 1996-10-17 1998-02-12 Henkel Kgaa Use of sterol sulphate compounds to inhibit serine protease
FR2755368B1 (en) 1996-11-04 1999-03-19 Oreal RINSABLE COMPOSITION FOR SKIN CARE
FR2757055B1 (en) 1996-12-17 1999-02-05 Oreal COMPOSITIONS CONSISTING OF DIBENZOYLMETHANE DERIVATIVE, 1,2,3-TRIAZINE DERIVATIVE AND DIALKYL BENZALMALONATE AND USES
FR2761601A1 (en) 1997-04-04 1998-10-09 Oreal SELF-TANNING COSMETIC COMPOSITIONS
JPH115742A (en) 1997-04-21 1999-01-12 Shiseido Co Ltd External preparation containing cholesterol sulfate
FR2763852B1 (en) 1997-05-28 1999-07-09 Oreal COMPOSITION COMPRISING A CINNAMIC ACID DERIVATIVE AND A POLYAMINE POLYMER
JPH1129468A (en) * 1997-07-09 1999-02-02 Shiseido Co Ltd Protease inhibitor
JPH1129467A (en) * 1997-07-09 1999-02-02 Shiseido Co Ltd Protease inhibitor
JPH11171758A (en) * 1997-12-12 1999-06-29 Maruzen Seiyaku Kk Elastase inhibitor and preparation for external use for skin
DE69914726T2 (en) * 1998-03-16 2004-12-02 The Procter & Gamble Company, Cincinnati COMPOSITION FOR REGULATING THE SKIN APPEARANCE
JPH11292777A (en) * 1998-04-08 1999-10-26 Lion Corp Extract containing forskolin and composition containing the extract
DE19824727A1 (en) * 1998-06-03 1999-12-09 Beiersdorf Ag Cosmetic or dermatological preparations containing catechins or green tea extract
DE19834812A1 (en) 1998-08-01 2000-02-03 Beiersdorf Ag Use of sterol derivatives, e.g., dihydrocholesterol, to strengthen the barrier function of skin, e.g., to protect against drying of skin and associated skin aging
US20020098207A1 (en) 1999-02-08 2002-07-25 Daniel H. Maes Cholesterol sulfate compositions for enhancement of stratum corneum function

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995025524A1 (en) * 1994-03-18 1995-09-28 Lvmh Recherche USE OF GINSENOSIDE Ro OR A PLANT EXTRACT CONTAINING SAME TO PROMOTE COLLAGEN SYNTHESIS
EP0717983A1 (en) * 1994-12-20 1996-06-26 Unilever Plc Cosmetic compositions containing betulinic acid
WO1999024009A1 (en) * 1997-11-07 1999-05-20 Lvmh Recherche Uses of d-xylose, the esters thereof and oligosaccharides containing xylose for improving the functionality of epidermal cells
WO1999062481A1 (en) * 1998-05-29 1999-12-09 Guerlain S.A. Cosmetic treatment method for fighting against skin ageing effects
WO1999063978A2 (en) * 1998-06-09 1999-12-16 R.J. Reynolds Tobacco Company Methods of treating microbial infection and therapeutic formulations therefor
EP0976396A1 (en) * 1998-07-30 2000-02-02 L'oreal Cosmetic or pharmaceutical patch and packaging

Cited By (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6576660B1 (en) 1997-10-31 2003-06-10 Arch Development Corporation Methods and compositions for regulation of 5-α-reductase activity
US6696484B2 (en) 1997-10-31 2004-02-24 University Of Chicago Office Of Technology And Intellectual Property Method and compositions for regulation of 5-alpha reductase activity
WO2002030385A2 (en) * 2000-09-30 2002-04-18 Henkel Kommanditgesellschaft Auf Aktien Anti-inflammatory active ingredients
WO2002030385A3 (en) * 2000-09-30 2002-11-14 Henkel Kgaa Anti-inflammatory active ingredients
WO2002080880A2 (en) * 2002-05-02 2002-10-17 Priscilla S.R.L. Unipersonale Anti-stretch mark preparation and method thereof
WO2002080880A3 (en) * 2002-05-02 2004-02-26 Priscilla S R L Unipersonale Anti-stretch mark preparation and method thereof
EP1442736A1 (en) * 2003-02-03 2004-08-04 L'oreal Use of 3-acetyl-11-keto-boswellic acid or of a plant extract containing the same for the reduction of wrinkles
FR2850573A1 (en) * 2003-02-03 2004-08-06 Oreal USE OF 3-ACETYL 11-KETO-BOSWELLIC ACID OR PLANT EXTRACT BY CONTAINING TO REDUCE EXPRESSION WRINKLES
WO2005105019A1 (en) * 2004-04-30 2005-11-10 Kao Corporation Winkle reduction agent and cosmetic skin preparation
US7611737B2 (en) 2004-04-30 2009-11-03 Kao Corporation Antiwrinkle agent and skin cosmetic composition
US8084064B2 (en) 2004-04-30 2011-12-27 Kao Corporation Antiwrinkle agent and skin cosmetic composition
WO2006007487A3 (en) * 2004-07-01 2006-08-17 E L Management Corp Cosmetic compositions and methods containing a tanning agent and liposome-enscapsulated ursolic acid
AU2005262369B2 (en) * 2004-07-01 2008-08-28 E-L Management Corp. Cosmetic compositions and methods containing a tanning agent and liposome-encapsulated ursolic acid
KR100871962B1 (en) * 2004-07-01 2008-12-08 이-엘 매니지먼트 코포레이션 Cosmetic compositions and methods containing a tanning agent and liposome-encapsulated ursolic acid
US7794694B2 (en) 2004-07-01 2010-09-14 E-L Management Corp. Cosmetic compositions and methods containing a tanning agent and liposome encapsulated ursolic acid
WO2008155048A1 (en) * 2007-06-20 2008-12-24 Cognis Ip Management Gmbh Cosmetic compositions comprising sclareolide and hesperidin methyl chalcone
EP2014276A1 (en) * 2007-06-20 2009-01-14 Cognis IP Management GmbH Cosmetic compositions comprising sclareolide and hesperidin methyl chalcone
EP2724712A1 (en) * 2007-06-20 2014-04-30 Cognis IP Management GmbH Cosmetic compositions comprising sclareolide and hesperidin methyl chalcone
US20100183527A1 (en) * 2007-06-20 2010-07-22 Cognis Ip Management Gmbh Cosmetic Compositions Comprising Sclareolide and Hesperidin Methyl Chalcone
WO2009138582A3 (en) * 2008-04-29 2010-03-11 Am Phyto-Conseil Use of a composition containing 7-dehydrocholesterol or a natural extract of a vegetable or animal microorganism
WO2009138582A2 (en) * 2008-04-29 2009-11-19 Am Phyto-Conseil Use of a composition containing 7-dehydrocholesterol or a natural extract of a vegetable or animal microorganism
FR2930445A1 (en) * 2008-04-29 2009-10-30 Am Phyto Conseil Sarl USE OF A COMPOSITION CONTAINING 7-DEHYDROCHOLESTEROL OR A NATURAL EXTRACT OF MICROORGANISM OR PLANT VEGETABLE OR ANIMAL
US20100040706A1 (en) * 2008-06-06 2010-02-18 Lvmh Recherche Method of anti-ageing cosmetic care by stimulation of survivin expression
FR2942962A1 (en) * 2009-03-11 2010-09-17 Oreal Cosmetic process for caring skin, which is fragile and damaged by chemical, mechanical and/or physical treatment, comprises applying a composition comprising at least one dihydrochalcone or its derivatives, in a medium, on the skin
WO2013038316A1 (en) 2011-09-12 2013-03-21 Stora Enso Oyj Method for preparation of betulinic acid
WO2013038314A1 (en) 2011-09-12 2013-03-21 Stora Enso Oyj Method for preparation of betulinic acid
EP2789369A1 (en) 2013-04-14 2014-10-15 Symrise AG A composition for lightening skin and hair
EP3133939A4 (en) * 2014-04-23 2018-03-28 Lifeline Nutraceuticals Corporation Topical compositions and methods for reducing oxidative stress
WO2016188988A1 (en) 2015-05-28 2016-12-01 Symrise Ag Cosmetic compositions comprising e/z-2-benzylindene-5,6-dimethoxy-3,3-dimethylindan-1-one
WO2016189046A1 (en) 2015-05-28 2016-12-01 Symrise Ag Cosmetic compositions comprising purple coneflower pressed juice
WO2016189024A1 (en) 2015-05-28 2016-12-01 Symrise Ag Cosmetic compositions comprising sclareolide
WO2016189038A1 (en) 2015-05-28 2016-12-01 Symrise Ag Cosmetic compositions comprising ginger root extracts
EP3097905A1 (en) 2015-05-28 2016-11-30 Symrise AG Cosmetic compositions
WO2017215729A1 (en) 2016-05-30 2017-12-21 Symrise Ag Cosmetic compositions comprising sclareolide
WO2018001485A1 (en) 2016-06-30 2018-01-04 Symrise Ag Medicament and cosmetic composition comprising resorcinol derivatives
WO2023167867A1 (en) 2022-03-01 2023-09-07 Isp Investments Llc Sclareol or sclareolide for improving scalp conditions and hair growth
WO2023167894A1 (en) * 2022-03-01 2023-09-07 Isp Investments Llc Sclareol or sclareolide for use in the treatment of inflammatory skin conditions

Also Published As

Publication number Publication date
CA2374763C (en) 2008-09-30
US20130095046A1 (en) 2013-04-18
AU782378B2 (en) 2005-07-21
PT1272154E (en) 2004-11-30
DE60014180T2 (en) 2005-10-06
JP2003528904A (en) 2003-09-30
KR20020040670A (en) 2002-05-30
AU4193100A (en) 2001-10-15
KR100596595B1 (en) 2006-07-06
US20080213202A1 (en) 2008-09-04
EP1272154A1 (en) 2003-01-08
DK1272154T3 (en) 2005-01-31
US8710034B2 (en) 2014-04-29
HK1056821B (en) 2005-03-18
HK1056821A1 (en) 2004-03-05
ATE276736T1 (en) 2004-10-15
CA2374763A1 (en) 2001-10-11
ES2225123T3 (en) 2005-03-16
EP1272154B1 (en) 2004-09-22
DE60014180D1 (en) 2004-10-28

Similar Documents

Publication Publication Date Title
US8710034B2 (en) Method and composition for improving skin barrier function
EP0855904B1 (en) Barrier disruption treatments for structurally deteriorated skin
KR100876742B1 (en) Skin Normalizing Agents
US5505948A (en) Home skin peel composition for producing healthy and attractive skin
US20110183018A9 (en) Cholesterol Sulfate And Amino Sugar Compositions For Enhancement Of Stratum Corneum Function
AU727993B2 (en) Topical composition and method for enhancing lipid barrier synthesis
US20170172964A1 (en) Composition for Treatment of Skin
WO2008139182A2 (en) Skin care composition
WO2019104222A1 (en) Methods and compositions for treatment of skin
KR20070000599A (en) Composition of skin external for improving skin barrier function
ZA200109705B (en) Composition for improving skin lipid barrier function.
US6716437B1 (en) Topical composition and method for enhancing lipid barrier synthesis

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 09554984

Country of ref document: US

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2374763

Country of ref document: CA

Ref country code: CA

Ref document number: 2374763

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2001/09705

Country of ref document: ZA

Ref document number: 200109705

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 1020017015406

Country of ref document: KR

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 572072

Kind code of ref document: A

Format of ref document f/p: F

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2000921641

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020017015406

Country of ref document: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2000921641

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 2000921641

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1020017015406

Country of ref document: KR